|
> Medical Science
Two randomized, double-blind clinical studies have been conducted to validate the effectiveness of the OnTrak Medical Treatment Program in a clinical environment. Results from these studies, address different substance dependencies to different substance across different populations, and, when viewed together, support the OnTrak Medical Treatment Program as an effective treatment in reducing cravings among members in alcohol and methamphetamine withdrawal.
1.) Harold Urschel, Research Across America, Dallas, Texas. - Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Flumazenil and Gabapentin in Reducing Craving and Use During use during Initial Treatment of Methamphetamine Dependence, published in the Journal of Psychopharmacology, November 25, 2009.
| > |
Immediately following the first 3 infusions, the combined craving score decreased by 54% in the treatment group, compared to a 35% decrease in the placebo group. |
| > |
Positive urine drug screens were statistically significantly lower for the OnTrak group overall. On any given day, the OnTrak subjects had a lower proportion of positive urine drug screens. |
| > |
Consecutive clean urines represent a longer abstinence period. Two consecutive clean urines in the four week study occurred in 42% of the treated subjects and 27% of the placebo subjects, which was statistically significant. |
| > |
The reduction in craving was highly correlated with predicting use within this study. This is consistent with literature on the importance of cravings in driving use. |
OnTrak- treated subjects had a lower percent of methamphetamine use by self-report.
2.) Raymond Anton, Medical University of South Carolina, Charleston, SC. - Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence, published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.
| > |
The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo. |
| > |
Among members with more symptoms of alcohol withdrawal, the Prometa group experienced: |
| |
- Reduction in alcohol withdrawal symptoms
- Promoted abstinence
- Reduced relapse
- Less heavy drinking days
- Less fatigue
- Improved mood
- Better sleep
- Medications were well tolerated
- The protocol may be ineffective for members who have fewer symptoms of alcohol withdrawal.
|
|
